13. References
13 References
63. Benhamou Y et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology, 1999, 30:1054–1058. 64. Deng LP et al. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. World Journal of Gastroenterology, 2009, 15:996–1003. 65. Pineda JA et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology, 2005, 41:779–789. 66. Thein HH et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS , 2008, 22:1979–1991. 67. Castel AD et al. Use of the community viral load as a population-based biomarker of HIV burden. AIDS , 2012, 26:345–353. 68. Cowan SA et al. Stable incidence of HIV diagnoses among Danish MSM despite increased engagement in unsafe sex. Journal of Acquired Immune Deficiency Syndromes . 2012, 61:106–111. 69. Das M et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE , 2010, 5:e11068. 70. Fang C-T et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. Journal of Infectious Diseases , 2004, 190:879–885. 71. Hogg RS et al. HAART-related decrease in the rate of new HIV diagnoses – a unique trend. 19th Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5–8 March 2012 (http://retroconference.org/2012b/ Abstracts/42768.htm, accessed 15 May 2013). 72. Geng EH et al. The effect of a “universal antiretroviral therapy” recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting. Clinical Infectious Diseases , 2012, 55:1690–1697. 73. Katz MH et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. American Journal of Public Health , 2002, 92:388–394. 74. Law MG et al. Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 2011, 14:10. 75. Manavi K et al. Community viral load counts and new HIV-positive patients in Birmingham, United Kingdom, between 2006 and 2011. XIX International AIDS Conference, Washington, DC, USA, 22–27 July 2012 (Abstract TUPE213; www.iasociety. org/Abstracts/A200747416.aspx, accessed 15 May 2013). 76. Montaner JS et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet , 2010, 376:532–539. 77. Montaner J et al. Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and new HIV diagnoses: an update on the ‘treatment as prevention’ experience in British Columbia, Canada. XIX International AIDS Conference, Washington, DC, USA, 22–27 July 2012 (Abstract THPE103; www.iasociety.org/Abstracts/A200745196.aspx, accessed 15 May 2013). 78. Porco TC et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS, 2004, 18:81–88. 79. Wood E et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. British Medical Journal, 2009, 338:b1649. Strategic timing of antiretroviral treatment (START) . Minneaolis, Clinical and Translational Science Institute, University of 80. Minnesota, 2012 (http://apps.who.int/trialsearch/Trial.aspx?TrialID =EUCTR2008-006439-12-FI, accessed 15 May 2013). 81. E arly antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). Paris, French National Agency for Research on AIDS and Viral Hepatitis, 2012 (http://apps.who.int/trialsearch/ Trial.aspx?TrialID =NCT00495651, accessed 15 May 2013). 82. A ntiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach. 2010 version . Geneva, World Health Organization, 2010 (http://whqlibdoc.who.int/ publications/2010/9789241599818_eng.pdf, accessed 15 May 2013). 83. C ountdown to zero: global plan for the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011–2015. Geneva, UNAIDS, 2011 (http://www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2011/20110609_JC2137_Global-Plan-Elimination-HIV-Children_en.pdf, accessed 15 May 2013). 84. Schouten EJ et al. Prevention of mother-to-child transmission of HIV and the health-related Millennnium Development Goals: time for a public health approach. Lancet , 2011, 378:282–284. I ntegrated HIV program report July–September 2012. Lilongwe, Ministry of Public Health, Government of Malawi (http:// 85. www.hivunitmohmw.org/uploads/Main/Quarterly_HIV_Programme_Report_2012_Q3.pdf, accessed 15 May 2013). 86. United States Centers for Disease Control and Prevention. Impact of an innovative approach to prevent mother-to-child transmission of HIV – Malawi, July 2011 –September 2012. MMWR Morbidity and Mortality Weekly Report , 2013, 62:148–151. U se of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: programmatic update. 87. Geneva, World Health Organization, 2012 (http://www.who.int/hiv/pub/mtct/programmatic_update2012/en/index.html, accessed 15 May 2013). 88. Taha TE et al. Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. Journal of Acquired Immune Deficiency Syndromes , 2011, 57:319–325. 89. The Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infectious Diseases , 2011, 11:171–180. 90. Coovadia HM et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomized, double-blind, placebo-controlled trial. Lancet , 2012, 379:221–228. 91. Jamieson DJ et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission (the BAN Study Group). New England Journal of Medicine, 2010, 362:2271–2281.
257